Clinical Trials Logo

Traumatic Spinal Cord Injury clinical trials

View clinical trials related to Traumatic Spinal Cord Injury.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06463418 Not yet recruiting - Clinical trials for Traumatic Spinal Cord Injury

Exoskeleton Training for Spinal Cord Injury Neuropathic Pain (ExSCIP)

ExSCIP
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

The goal of this feasibility trial is to learn if exoskeleton or robotic walking works to reduce nerve (neuropathic) pain after spinal cord injury. This study asks is: - Providing walking practice through use of a robotic device (exoskeleton) three times per week for twelve weeks possible to deliver? - Would people sign up and stick to the programme? - And will it help to reduce neuropathic pain levels after spinal injury? Researchers will compare robotic walking and a relaxation program to see if robotic walking works to reduce neuropathic pain levels after spinal injury. Participants will: - Complete a number of questionnaires and tests related to their pain before the trial. - Complete robotic walking or a relaxation program three times per week for twelve weeks. - Complete the same questionnaires and tests after the trial finishes and 6 months after. - Complete an interview telling researchers about their experiences of the trial.

NCT ID: NCT06247904 Not yet recruiting - Clinical trials for Tetraplegia/Tetraparesis

NIBS Therapy in Subacute Spinal Cord Injury

NIBS-SCI1
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

No accepted clinical therapies exist for repair of motor pathways following spinal cord injury (SCI) in humans, leaving permanent disability and devastating personal and socioeconomic cost. A robust neural repair strategy has been demonstrated in preclinical studies, that is ready for translation to recovery of hand and arm function in human SCI, comprising daily transcranial magnetic stimulation treatment at the inpatient rehabilitation facility. This study will establish clinical effect size of the intervention, as well as safety and feasibility necessary for a subsequent controlled efficacy trial and inform preclinical studies for dosing optimization.